T1	Participants 26 48	in early breast cancer
T2	Participants 447 640	in 624 (94%) and 462 (69%), respectively, of 667 postmenopausal women with hormone responsive early breast cancer treated by surgery followed by adjuvant treatment with tamoxifen +/- octreotide
T3	Participants 680 750	National Cancer Institute of Canada Clinical Trials Group Mammary.14).
T4	Participants 1626 1694	women with hormone responsive early breast cancer in the MA.14 trial
